nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—forebrain—attention deficit hyperactivity disorder	0.0279	0.092	CbGeAlD
Irbesartan—JUN—cardiovascular system—attention deficit hyperactivity disorder	0.0236	0.0778	CbGeAlD
Irbesartan—AGTR1—forebrain—attention deficit hyperactivity disorder	0.021	0.0693	CbGeAlD
Irbesartan—EDNRA—midbrain—attention deficit hyperactivity disorder	0.0202	0.0666	CbGeAlD
Irbesartan—JUN—midbrain—attention deficit hyperactivity disorder	0.0185	0.0608	CbGeAlD
Irbesartan—AGTR1—cardiovascular system—attention deficit hyperactivity disorder	0.0178	0.0586	CbGeAlD
Irbesartan—JUN—nervous system—attention deficit hyperactivity disorder	0.0152	0.05	CbGeAlD
Irbesartan—JUN—central nervous system—attention deficit hyperactivity disorder	0.0146	0.0481	CbGeAlD
Irbesartan—JUN—cerebellum—attention deficit hyperactivity disorder	0.0143	0.047	CbGeAlD
Irbesartan—EDNRA—brain—attention deficit hyperactivity disorder	0.0127	0.0419	CbGeAlD
Irbesartan—JUN—brain—attention deficit hyperactivity disorder	0.0116	0.0382	CbGeAlD
Irbesartan—AGTR1—nervous system—attention deficit hyperactivity disorder	0.0114	0.0376	CbGeAlD
Irbesartan—AGTR1—central nervous system—attention deficit hyperactivity disorder	0.011	0.0362	CbGeAlD
Irbesartan—PTGS1—forebrain—attention deficit hyperactivity disorder	0.00925	0.0305	CbGeAlD
Irbesartan—AGTR1—brain—attention deficit hyperactivity disorder	0.00873	0.0288	CbGeAlD
Irbesartan—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.00857	0.0282	CbGeAlD
Irbesartan—PTGS1—cardiovascular system—attention deficit hyperactivity disorder	0.00782	0.0258	CbGeAlD
Irbesartan—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.0076	0.025	CbGeAlD
Irbesartan—PTGS1—nervous system—attention deficit hyperactivity disorder	0.00502	0.0165	CbGeAlD
Irbesartan—PTGS1—central nervous system—attention deficit hyperactivity disorder	0.00484	0.0159	CbGeAlD
Irbesartan—CYP2C8—brain—attention deficit hyperactivity disorder	0.00473	0.0156	CbGeAlD
Irbesartan—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00419	0.0138	CbGeAlD
Irbesartan—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.00413	0.0136	CbGeAlD
Irbesartan—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00404	0.0133	CbGeAlD
Irbesartan—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.00397	0.0131	CbGeAlD
Irbesartan—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.00388	0.0128	CbGeAlD
Irbesartan—PTGS1—brain—attention deficit hyperactivity disorder	0.00384	0.0126	CbGeAlD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00339	0.00487	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00333	0.00478	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.00329	0.00473	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.00329	0.00473	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00327	0.00469	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00327	0.00469	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00323	0.00464	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.00319	0.00458	CbGpPWpGaD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00316	0.00454	CbGpPWpGaD
Irbesartan—CYP2D6—brain—attention deficit hyperactivity disorder	0.00316	0.0104	CbGeAlD
Irbesartan—JUN—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00312	0.00448	CbGpPWpGaD
Irbesartan—JUN—Regulation of Androgen receptor activity—EP300—attention deficit hyperactivity disorder	0.00311	0.00447	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.0031	0.00445	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00309	0.00444	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00309	0.00443	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00307	0.00441	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—EP300—attention deficit hyperactivity disorder	0.00306	0.0044	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00304	0.00436	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00301	0.00432	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.003	0.00431	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.003	0.0043	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00294	0.00423	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00293	0.00421	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00291	0.00418	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00291	0.00417	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.0029	0.00416	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.00288	0.00414	CbGpPWpGaD
Irbesartan—AGTR1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00287	0.00411	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00286	0.0041	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00285	0.0041	CbGpPWpGaD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00282	0.00405	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00282	0.00405	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00279	0.00401	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00276	0.00396	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00274	0.00393	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00271	0.00389	CbGpPWpGaD
Irbesartan—JUN—Validated nuclear estrogen receptor alpha network—EP300—attention deficit hyperactivity disorder	0.00267	0.00384	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00263	0.00378	CbGpPWpGaD
Irbesartan—JUN—Regulation of retinoblastoma protein—EP300—attention deficit hyperactivity disorder	0.00261	0.00375	CbGpPWpGaD
Irbesartan—JUN—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.00261	0.00375	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00256	0.00368	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00253	0.00364	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00249	0.00358	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00249	0.00357	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00247	0.00355	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00246	0.00353	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00242	0.00347	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00241	0.00346	CbGpPWpGaD
Irbesartan—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00238	0.00342	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00236	0.00339	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00236	0.00338	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00228	0.00328	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00226	0.00325	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00224	0.00322	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—attention deficit hyperactivity disorder	0.00224	0.00321	CbGpPWpGaD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00221	0.00318	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—EP300—attention deficit hyperactivity disorder	0.00221	0.00318	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00221	0.00318	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—EP300—attention deficit hyperactivity disorder	0.00219	0.00315	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00219	0.00315	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00215	0.00308	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00209	0.003	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00206	0.00296	CbGpPWpGaD
Irbesartan—JUN—Androgen receptor signaling pathway—EP300—attention deficit hyperactivity disorder	0.00205	0.00295	CbGpPWpGaD
Irbesartan—PTGS1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00197	0.00283	CbGpPWpGaD
Irbesartan—PTGS1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00196	0.00281	CbGpPWpGaD
Irbesartan—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00196	0.00281	CbGpPWpGaD
Irbesartan—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00194	0.00279	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00193	0.00277	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00192	0.00276	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.0019	0.00272	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.0019	0.00272	CbGpPWpGaD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—EP300—attention deficit hyperactivity disorder	0.00184	0.00264	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00184	0.00264	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00182	0.00262	CbGpPWpGaD
Irbesartan—JUN—Immune System—MB21D1—attention deficit hyperactivity disorder	0.0018	0.00258	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—EP300—attention deficit hyperactivity disorder	0.00175	0.00251	CbGpPWpGaD
Irbesartan—JUN—Immune System—STUB1—attention deficit hyperactivity disorder	0.00174	0.0025	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.0017	0.00244	CbGpPWpGaD
Irbesartan—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00166	0.00238	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00166	0.00238	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00165	0.00237	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00164	0.00236	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00164	0.00235	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00162	0.00232	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00161	0.00232	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.0016	0.00229	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00158	0.00228	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00154	0.00221	CbGpPWpGaD
Irbesartan—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00152	0.00218	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00151	0.00216	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.0015	0.00215	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00149	0.00214	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00149	0.00214	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00149	0.00213	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00147	0.00211	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00145	0.00208	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00145	0.00207	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00144	0.00207	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00143	0.00206	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00143	0.00206	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—EP300—attention deficit hyperactivity disorder	0.00143	0.00205	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00135	0.00194	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00135	0.00193	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00133	0.00191	CbGpPWpGaD
Irbesartan—JUN—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00132	0.00189	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00131	0.00188	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.0013	0.00187	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00129	0.00186	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00129	0.00185	CbGpPWpGaD
Irbesartan—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00128	0.00184	CbGpPWpGaD
Irbesartan—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00127	0.00183	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00127	0.00182	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00127	0.00182	CbGpPWpGaD
Irbesartan—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00127	0.00182	CbGpPWpGaD
Irbesartan—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00126	0.00181	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00125	0.0018	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00124	0.00179	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00121	0.00174	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00117	0.00168	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00117	0.00167	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00115	0.00165	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00114	0.00163	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00113	0.00162	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00112	0.00161	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00112	0.0016	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00109	0.00157	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00109	0.00157	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.00107	0.00154	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00106	0.00152	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00105	0.0015	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00104	0.00149	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00104	0.00149	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00104	0.00149	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00103	0.00148	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00103	0.00148	CbGpPWpGaD
Irbesartan—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00102	0.00147	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000989	0.00142	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000989	0.00142	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000979	0.00141	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000973	0.0014	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000967	0.00139	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000947	0.00136	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000945	0.00136	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000929	0.00133	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00091	0.00131	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000905	0.0013	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000887	0.00127	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000881	0.00127	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00088	0.00126	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000879	0.00126	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000875	0.00126	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000866	0.00124	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000861	0.00124	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000856	0.00123	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000817	0.00117	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000807	0.00116	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000797	0.00114	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000791	0.00114	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000768	0.0011	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000753	0.00108	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000742	0.00106	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000714	0.00103	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000692	0.000993	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000684	0.000983	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00068	0.000976	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00068	0.000976	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000675	0.000969	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000671	0.000964	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000657	0.000943	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000625	0.000898	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000599	0.000861	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000595	0.000854	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000574	0.000824	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000558	0.000802	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000557	0.0008	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000557	0.0008	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000548	0.000787	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000534	0.000766	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000521	0.000749	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000517	0.000742	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00051	0.000732	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000508	0.000729	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000502	0.00072	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000467	0.000671	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.00046	0.000661	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000445	0.00064	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000438	0.000629	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000428	0.000615	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000424	0.000609	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000424	0.000609	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000363	0.000521	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00036	0.000517	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00036	0.000517	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000354	0.000508	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000338	0.000485	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000335	0.000481	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000329	0.000473	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000327	0.00047	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000325	0.000467	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000296	0.000425	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000295	0.000424	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000295	0.000424	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000293	0.000421	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000293	0.000421	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000291	0.000417	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000288	0.000414	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000288	0.000413	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00028	0.000402	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000274	0.000393	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00027	0.000388	CbGpPWpGaD
Irbesartan—JUN—Immune System—EP300—attention deficit hyperactivity disorder	0.000268	0.000385	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000268	0.000385	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—EP300—attention deficit hyperactivity disorder	0.000257	0.000369	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00025	0.000359	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00025	0.000359	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000246	0.000354	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000236	0.000339	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000234	0.000336	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000232	0.000333	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000229	0.000329	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000225	0.000323	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000223	0.00032	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	0.000218	0.000313	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000217	0.000311	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00021	0.000301	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.0002	0.000287	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000193	0.000277	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000193	0.000277	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00019	0.000274	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00019	0.000273	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	0.000179	0.000257	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000178	0.000255	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000177	0.000255	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000177	0.000254	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000176	0.000253	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000173	0.000249	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000171	0.000245	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000154	0.000222	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000152	0.000218	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000151	0.000216	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000147	0.000211	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000146	0.00021	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000145	0.000208	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000117	0.000168	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000116	0.000167	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	9.35e-05	0.000134	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	7.68e-05	0.00011	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	7.61e-05	0.000109	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	6.5e-05	9.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	5.02e-05	7.21e-05	CbGpPWpGaD
